Search results for "Alzheimer"

CHARACTERIZATION OF THE SYNAPTIC PROTEOME IN NON-DEMENTED SUBJECTS WITH ALZHEIMER’S NEUROPATHOLOGY

Some individuals, here refereed to as Non-Demented with Alzheimer’s Neuropathology (NDAN), retain their congitive function despite the presence of amyloid plaques and tau tangles typical of symptomatic Alzheimer’s Disease (AD). In NDAN, unlike AD, toxic amyloid beta oligomers do not localize to the postsynaptic densities (PSDs). Synaptic resistance to amyloid beta in NDAN may thus enable these individuals to remain cognitively intact despite the AD-like pathology. The mechanim(s) responsible for this resistance remains unresolved and understanding such protective biological processes could reveal novel targets for the development of effective treatments for AD. The current work describes th…

SYNTHESIS AND EVALUATION OF CURCUMIN ANALOGUES AS NEURO-PROTECTIVE AGENTS FOR THE ALZHEIMER'S DISEASE

2013

The Alzheimer's disease (AD) is the most common form of senile dementia.1 The most important role in AD is played by the aggregation process of beta-amyloid peptide (Aß), responsible for the cytotoxic effects.2 In this context, the purpose of this study was to synthesize new dicarbonyl compounds 1 structurally related to curcumin3, with anti-aggregation activity against Aß.Parallel studies involve the synthesis of heterocyclic-based curcumin-like molecules that are currently under investigation by means of in silico protocols in order to rationalize the ligand-biological target interactions.

EPIGENETIC REGULATION OF NEUROGENESIS IN NON-DEMENTED HUMANS WITH ALZHEIMER’S DISEASE NEUROPATHOLOGY

This project was designed to investigate the role of neurogenesis and its epigenetic regulation by microRNA in the preservation of cognition against Alzheimer’s disease. This was accomplished by comparing by immunohistochemistry the capacity for neurogenesis in the subgranular zone of the hippocampus in 4 distinct populations of human subject’s tissue representing the full disease, intermediate cognitive decline, healthy controls, and a poorly characterized group who have all of the histopathological hallmarks of the full disease but are cognitively normal. To investigate the microRNAs of interest in the correct context, as microRNA expression can vary significantly by region, the granular …

Near infrared light to promote synaptic resilience to Alzheimer’s Disease neuropathology

Alzheimer’s Disease (AD) is a multifactorial neurodegenerative dementia with no curative therapeutic options. One of the earliest impairments in AD triggering cognitive decline is the synaptic dysfunction induced by the selective targeting and interruption of the synaptic region by the small oligomeric form of amyloid beta (Aβ). Recently, the co-presence of Aβ oligomers (Aβo) and tau oligomers (tau-o) at the synapses has been suggested to exacerbate this dysfunction. Therefore, the development of therapeutics aimed at protecting the synapses from the toxic binding of both proteins at the synapses can preserve synaptic health and cognitive function. With this goal in mind, the present study …

Studio di segmentazione morfovolumetrica in pazienti con declino cognitivo lieve amnestico (aMCI) e demenza di Alzheimer (AD) rispetto ad un gruppo d…

2016

SCOPO: Presentare i risultati preliminari di un’analisi di segmentazione morfovolumetrica (VBM) eseguita in pazienti con aMCI ed AD rispetto ad una popolazione di controllo (NAB). Tali dati saranno in futuro correlati ad altri parametri clinico-psicologici raccolti (età, sesso, scolarità, MMSE, ADL, IADL). MATERIALI E METODI: Sono stati sottoposti ad esame RM encefalo 103 soggetti, utilizzando uno scanner RM GE Signa HDxt da 1,5T ed acquisendo, tra le altre, una sequenza Sag 3D T1 FSPGR IR preped ASSET che è stata utilizzata per l’analisi VBM eseguita con il tool sienax (FSL). I risultati sono stati valutati in termini di valori medi e deviazioni standard mediante applicazione del t-test…

Coconut oil: non-alternative drug treatment against alzheimer's disease

2015

Introducción: la enfermedad de Alzheimer es la demencia más prevalente en la actualidad. En cuanto al tratamiento, no existe cura farmacológica definitiva, con lo cual son necesarias nuevas alternativas terapéuticas. En este sentido, los triglicéridos de cadena media suponen una fuente directa de energía celular y pueden ser una alternativa no farmacológica a la muerte neuronal por falta de la misma, que se produce en los enfermos de Alzheimer. Objetivo: evaluar el impacto que tiene el aceite de coco en la evolución de la demencia tipo Alzheimer, en cualquier grado de demencia. Asimismo, determinar si existe influencia en dicha mejora, de variables como el sexo y padecer o no diabetes melli…

Targeting Alzheimer’s disease with multimodal polypeptide-based nanoconjugates

2021

LRP1-targeted St-Cl–polyglutamate conjugates as multivalent neuroprotective/neurotrophic therapeutics for Alzheimer’s disease.

Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer’s Disease from Other Neurological Disorders

2022

Recently, the synaptic proteins neurogranin (Ng) and α-synuclein (α-Syn) have attracted scientific interest as potential biomarkers for synaptic dysfunction in neurodegenerative diseases. In this study, we measured the CSF Ng and α-Syn concentrations in patients affected by AD (n = 69), non-AD neurodegenerative disorders (n-AD = 50) and non-degenerative disorders (n-ND, n = 98). The concentrations of CSF Ng and α-Syn were significantly higher in AD than in n-AD and n-ND. Moreover, the Aβ42/Ng and Aβ42/α-Syn ratios showed statistically significant differences between groups and discriminated AD patients from n-AD patients, better than Ng or α-Syn…

Genistein effect on cognition in prodromal Alzheimer's disease patients : the GENIAL clinical trial

2022

Background: Delaying the transition from minimal cognitive impairment to Alzheimer’s dementia is a major concern in Alzheimer’s disease (AD) therapeutics. Pathological signs of AD occur years before the onset of clinical dementia. Thus, long-term therapeutic approaches, with safe, minimally invasive, and yet efective substances are recommended. There is a need to develop new drugs to delay Alzheimer’s dementia. We have taken a nutritional supplement approach with genistein, a chemically defned polyphenol that acts by multimodal specifc mechanisms. Our group previously showed that genistein supplementation is efective to treat the double transgenic (APP/PS1) AD animal model. Methods: In this…

Gradient-echo and CRAZED imaging for minute detection of Alzheimer plaques in an APPV717I x ADAM10-dn mouse model.

2007

Different strategies to visualize amyloid plaques with MRI at 17.6 Tesla were investigated in a novel mouse model of Alzheimer's disease (AD). Large iron-containing plaques were observed in the thalamus, but cortical plaques did not show iron deposits. Plaques in the thalamus were visualized in vivo with the use of low-resolution, 3D gradient-echo (GRE) imaging in 82 s, and with 94-microm resolution in 34 min. The feasibility of obtaining bright contrast from plaques using the COSY revamped with asymmetric z-GRE detection (CRAZED) technique was investigated in experiments on fixed brains. The original CRAZED approach provided reduced signal near the plaques (similarly to GRE imaging) and ad…